Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idarubicin + etoposide + cytarabine + tretinoin + pegfilgrastim
- Development stage
- Phase 3
- Lead developer
- Ulm University
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This multi-agent chemotherapy regimen serves as the standard-of-care backbone in clinical trials conducted by the German-Austrian AML Study Group (AMLSG), specifically at the University of Ulm. It is primarily utilized for the treatment of adult patients with nucleophosmin-1 (NPM1)-mutated acute myeloid leukemia (AML). The regimen consists of an induction and consolidation phase featuring the antimetabolite cytarabine, the anthracycline idarubicin, and the topoisomerase II inhibitor etoposide (collectively known as the ICE regimen). This is supplemented with all-trans retinoic acid (ATRA/tretinoin), which acts as a differentiating agent to promote the maturation of leukemic blasts, and pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF) used to accelerate myeloid recovery and reduce the duration of neutropenia.
- Other names
- standard chemotherapy (University of Ulm)ICE + ATRA + Pegfilgrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)DNADNA polymerase familyTOP2A (DNA topoisomerase II)RARA (Retinoic acid receptor alpha)
Beyond the preview
Go deeper on idarubicin + etoposide + cytarabine + tretinoin + pegfilgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idarubicin + etoposide + cytarabine + tretinoin + pegfilgrastim.